Sam Chun Dang Pharm. Co., Ltd

KOSDAQ:A000250 Stock Report

Market Cap: ₩5.2t

Sam Chun Dang Pharm Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Sam Chun Dang Pharm.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth21.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Analysis Article • Mar 27

Sam Chun Dang Pharm (KOSDAQ:000250) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Sam Chun Dang Pharm. Co., Ltd's ( KOSDAQ:000250 ) stock was strong after they recently reported robust earnings...
Analysis Article • Dec 31

Sam Chun Dang Pharm (KOSDAQ:000250) Takes On Some Risk With Its Use Of Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Sep 19

Sam Chun Dang Pharm. Co., Ltd's (KOSDAQ:000250) 27% Share Price Surge Not Quite Adding Up

Despite an already strong run, Sam Chun Dang Pharm. Co., Ltd ( KOSDAQ:000250 ) shares have been powering on, with a...
Analysis Article • Jul 23

Sam Chun Dang Pharm. Co., Ltd's (KOSDAQ:000250) Shares Climb 28% But Its Business Is Yet to Catch Up

Sam Chun Dang Pharm. Co., Ltd ( KOSDAQ:000250 ) shares have continued their recent momentum with a 28% gain in the last...
Analysis Article • Jul 11

Here's Why Sam Chun Dang Pharm (KOSDAQ:000250) Has A Meaningful Debt Burden

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Apr 22

Risks Still Elevated At These Prices As Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Shares Dive 26%

Sam Chun Dang Pharm. Co., Ltd ( KOSDAQ:000250 ) shares have had a horrible month, losing 26% after a relatively good...
Analysis Article • Mar 27

We Think Sam Chun Dang Pharm (KOSDAQ:000250) Is Taking Some Risk With Its Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Feb 05

Revenues Not Telling The Story For Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) After Shares Rise 29%

Despite an already strong run, Sam Chun Dang Pharm. Co., Ltd ( KOSDAQ:000250 ) shares have been powering on, with a...
Analysis Article • Dec 22

Here's Why Sam Chun Dang Pharm (KOSDAQ:000250) Has A Meaningful Debt Burden

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Nov 30

Risks Still Elevated At These Prices As Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Shares Dive 26%

To the annoyance of some shareholders, Sam Chun Dang Pharm. Co., Ltd ( KOSDAQ:000250 ) shares are down a considerable...
Analysis Article • Oct 05

Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Investors Are Less Pessimistic Than Expected

When close to half the companies in the Pharmaceuticals industry in Korea have price-to-sales ratios (or "P/S") below...
Analysis Article • Sep 08

Sam Chun Dang Pharm (KOSDAQ:000250) Takes On Some Risk With Its Use Of Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Jun 19

Subdued Growth No Barrier To Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) With Shares Advancing 44%

Sam Chun Dang Pharm. Co., Ltd ( KOSDAQ:000250 ) shares have continued their recent momentum with a 44% gain in the last...
Analysis Article • Jun 09

Is Sam Chun Dang Pharm (KOSDAQ:000250) A Risky Investment?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article • Mar 21

Optimistic Investors Push Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Shares Up 28% But Growth Is Lacking

Sam Chun Dang Pharm. Co., Ltd ( KOSDAQ:000250 ) shareholders have had their patience rewarded with a 28% share price...
Analysis Article • Feb 26

Sam Chun Dang Pharm (KOSDAQ:000250) Seems To Use Debt Quite Sensibly

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Feb 09

Investors Who Bought Sam Chun Dang Pharm (KOSDAQ:000250) Shares Five Years Ago Are Now Up 644%

Sam Chun Dang Pharm. Co., Ltd ( KOSDAQ:000250 ) shareholders have seen the share price descend 20% over the month. But...
Analysis Article • Jan 05

Could The Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250) Ownership Structure Tell Us Something Useful?

Every investor in Sam Chun Dang Pharm. Co., Ltd ( KOSDAQ:000250 ) should be aware of the most powerful shareholder...
Analysis Article • Dec 01

Here's Why Sam Chun Dang Pharm (KOSDAQ:000250) Can Manage Its Debt Responsibly

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sam Chun Dang Pharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A000250 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2026246,05510,232-70,533-1,129N/A
12/31/2025231,8055,262-49,0929,793N/A
9/30/2025220,737-11,404-59,3045,451N/A
6/30/2025215,095-15,088-51,238-4,265N/A
3/31/2025213,084-11,578-26,90020,828N/A
12/31/2024210,924-10,916-19,53021,771N/A
9/30/2024208,2215,1106,80738,384N/A
6/30/2024204,281-5,59213,70035,294N/A
3/31/2024196,971-9,5996,91926,723N/A
12/31/2023192,669-10,3831,45523,428N/A
9/30/2023184,682-15,038-25,66410,825N/A
6/30/2023180,070-560-26,52812,920N/A
3/31/2023179,6734,368-26,35516,124N/A
12/31/2022177,3355,838-33,26713,279N/A
9/30/2022176,520-198-34,5489,114N/A
6/30/2022175,261-6,934-44,277-3,598N/A
3/31/2022169,530-10,486-43,109-9,015N/A
12/31/2021167,275-16,555-37,014-7,707N/A
9/30/2021163,026-5,672-25,246-7,925N/A
6/30/2021161,999-10,853-12,4891,108N/A
3/31/2021164,875-6,444-13,748232N/A
12/31/2020166,862-966-8,5483,250N/A
9/30/2020171,989-8,686-7,2541,948N/A
6/30/2020183,2077,8769,94920,559N/A
3/31/2020184,6468,58721,70932,140N/A
12/31/2019186,60210,452N/A30,603N/A
9/30/2019180,33311,503N/A33,071N/A
6/30/2019167,8808,364N/A23,010N/A
3/31/2019163,5229,368N/A21,947N/A
12/31/2018159,9608,754N/A25,034N/A
9/30/2018159,84713,072N/A28,126N/A
6/30/2018163,48112,992N/A21,851N/A
3/31/2018161,47211,398N/A20,084N/A
12/31/2017160,58712,515N/A26,087N/A
9/30/2017161,6788,014N/A16,245N/A
6/30/2017154,6637,412N/A20,315N/A
3/31/2017152,1909,066N/A20,498N/A
12/31/2016147,3738,712N/A17,764N/A
9/30/2016143,25313,355N/A24,256N/A
6/30/2016140,60013,228N/A23,298N/A
3/31/2016135,87112,180N/A21,981N/A
12/31/2015132,06211,628N/A17,342N/A
9/30/2015129,27410,956N/A18,539N/A
6/30/2015124,62410,390N/A18,961N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A000250's forecast earnings growth is above the savings rate (3.1%).

Earnings vs Market: Insufficient data to determine if A000250's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A000250's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A000250's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A000250's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A000250's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/24 23:19
End of Day Share Price 2026/06/24 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sam Chun Dang Pharm. Co., Ltd is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Al Eum LeeiM Securities
Hong-Sik JeongLS Securities Co., Ltd.
Seung Woo SonShinhan Investment Corp.